J&J, Bavarian Nordic and GSK involved in upcoming Ebola vax trials; Researchers develop rheumatoid arthritis immunotherapy;

> Upcoming Ebola vaccine trials in Ghana will be led by Johnson & Johnson ($JNJ) and Bavarian Nordic in Phase I and GlaxoSmithKline ($GSK) in Phase II. Report

> Australia's University of Queensland researchers developed an immunotherapy for people with the most common form of rheumatoid arthritis. More

> Cellular Biomedicine Group ($CBMG) acquired from Blackbird Bio Finance a cancer vaccine to be used in a trial of non-small cell lung cancer. Release

> A cancer vaccine from Australia's Regenus, originally tried in dogs, will be used in 21 humans with advanced cancers who have exhausted all available treatment regimens. Report

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.